A detailed history of Greenleaf Trust transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Greenleaf Trust holds 1,951 shares of REGN stock, worth $1.45 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,951
Previous 1,948 0.15%
Holding current value
$1.45 Million
Previous $2.05 Million 0.15%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$1024.09 - $1201.76 $3,072 - $3,605
3 Added 0.15%
1,951 $2.05 Million
Q2 2024

Jul 22, 2024

BUY
$883.2 - $1071.19 $42,393 - $51,417
48 Added 2.53%
1,948 $2.05 Million
Q1 2024

Apr 29, 2024

SELL
$902.69 - $993.35 $2,708 - $2,980
-3 Reduced 0.16%
1,900 $1.83 Million
Q4 2023

Jan 31, 2024

BUY
$775.18 - $881.7 $48,836 - $55,547
63 Added 3.42%
1,903 $1.67 Million
Q3 2023

Nov 09, 2023

SELL
$692.45 - $844.37 $22,158 - $27,019
-32 Reduced 1.71%
1,840 $1.51 Million
Q2 2023

Aug 09, 2023

SELL
$700.03 - $830.35 $109,904 - $130,364
-157 Reduced 7.74%
1,872 $1.35 Million
Q1 2023

May 11, 2023

BUY
$680.49 - $826.97 $58,522 - $71,119
86 Added 4.43%
2,029 $1.67 Million
Q4 2022

Jan 25, 2023

BUY
$705.89 - $766.39 $122,824 - $133,351
174 Added 9.84%
1,943 $1.4 Million
Q3 2022

Nov 10, 2022

BUY
$573.97 - $724.32 $175,634 - $221,641
306 Added 20.92%
1,769 $1.22 Million
Q2 2022

Aug 12, 2022

SELL
$548.35 - $738.84 $98,703 - $132,991
-180 Reduced 10.96%
1,463 $865,000
Q1 2022

Apr 27, 2022

BUY
$595.12 - $698.43 $116,048 - $136,193
195 Added 13.47%
1,643 $1.15 Million
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $17,391 - $21,471
32 Added 2.26%
1,448 $914,000
Q3 2021

Nov 12, 2021

BUY
$574.03 - $680.96 $15,498 - $18,385
27 Added 1.94%
1,416 $857,000
Q2 2021

Aug 10, 2021

BUY
$472.8 - $558.54 $38,769 - $45,800
82 Added 6.27%
1,389 $776,000
Q1 2021

Apr 30, 2021

BUY
$446.73 - $548.2 $119,276 - $146,369
267 Added 25.67%
1,307 $618,000
Q4 2020

Feb 08, 2021

SELL
$478.3 - $607.98 $68,875 - $87,549
-144 Reduced 12.16%
1,040 $502,000
Q3 2020

Oct 30, 2020

BUY
$544.75 - $658.21 $10,895 - $13,164
20 Added 1.72%
1,184 $663,000
Q2 2020

Aug 12, 2020

BUY
$493.32 - $643.92 $134,676 - $175,790
273 Added 30.64%
1,164 $726,000
Q1 2020

Apr 29, 2020

BUY
$336.18 - $494.43 $93,121 - $136,957
277 Added 45.11%
891 $435,000
Q4 2019

Feb 11, 2020

SELL
$274.13 - $376.51 $34,266 - $47,063
-125 Reduced 16.91%
614 $231,000
Q3 2019

Nov 08, 2019

BUY
$273.46 - $318.39 $202,086 - $235,290
739 New
739 $205,000
Q2 2019

Jul 24, 2019

SELL
$299.6 - $414.82 $297,203 - $411,501
-992 Closed
0 $0
Q1 2019

May 08, 2019

BUY
$372.08 - $439.57 $36,091 - $42,638
97 Added 10.84%
992 $407,000
Q4 2018

Feb 07, 2019

BUY
$335.82 - $403.04 $26,865 - $32,243
80 Added 9.82%
895 $334,000
Q3 2018

Oct 29, 2018

BUY
$351.14 - $408.51 $50,915 - $59,233
145 Added 21.64%
815 $329,000
Q2 2018

Aug 07, 2018

BUY
$284.6 - $344.99 $190,682 - $231,143
670 New
670 $231,000
Q1 2018

Apr 30, 2018

SELL
$315.82 - $393.78 $13,580 - $16,932
-43 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$431.38 - $504.0 $18,549 - $21,672
43
43 $19,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $79.7B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Greenleaf Trust Portfolio

Follow Greenleaf Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenleaf Trust, based on Form 13F filings with the SEC.

News

Stay updated on Greenleaf Trust with notifications on news.